Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Best news for a long time. Congrats all. Very happy Christmas
Impressive numbers considering all the logistics issues that needed overcoming. Going the right way and so steady. Well done all
It's exceptionally good news from the FDA. Early trial stages must have been very positive.
Hugely exciting times ahead.
Unfortunately this perpetuates the show for certain posters. The skilful way in which they post plausible downers on the stock works well, serves their agenda they know it. It happens across virtually every aim and is a continual blur on the real function of the board. (They say it provides balance, which it doesn’t)
The best response is always no response.
I think we all know deep down that this stock is ultimately destined for great things, despite the bumpy road and will ultimately prove to be a great success.
Roundhowe, I sympathise. I had a similar horrific experience with Xpress Test at the airport a few months ago. This was inside the terminal and was staffed by Easy Jet stewards. It was quite like a chaotic episode of The Apprentice; manic and disorganised. The supposed PCR tests were wrong and I evidenced that at significant cost and hassle.
This Company does my head in but I will be doubling my stake in the coming week. Always held and will continue to. I don’t really think it is 2 pronged, with a proper diagnostics business. I don’t think their heart has really been there and they don’t have the temperament the cut and thrust scale, logistics and politics. I get the felling that science and manufacturing are at odds.
I do however think that the therapeutics business could be the best punt I’ll ever have and I think what they’re doing is extremely clever.
I do agree. The numbers were notably up today.
I note PL75’s sensible post earlier today, recognising the ‘not to be sniffed at’ numbers. This is very true and taking a frugal view on the business. It doesn’t take much to provide easy going revenue streams to make our business quite appealing and more than wash its face.
I keep re reading the research material on therapeutics and, if any of this comes off, it is quite mesmerising. One couldn’t honestly put a figure on valuation. Feet on the ground for just now. Step by step but it could be completely real. Valuations go out of the windows if it goes all the way. Might take some time still but time passes quickly, as we all know.
Good thread Poirot. Radiagreen, think you’re right. Would seem inevitable that LG would be our eventual acquisitor.
LG is my my most positive feeling about progress for us in terms of speed to market. It’s appears to be a great relationship for 3 main reasons: they potentially prove our worth, pay us along the way and then exit us.
Was dreading this presentation but decided to tune in. So much better than previous ones. A lot more honest and robust in delivery. No surprises on AffidX other than it is selling and is likely to increase and more than support the cash position for some time to come. Clearly AVA6000 is going the right way, for now, which is by far the most telling takeaway. My bet also on LG to kick things off in a big way aswell.
I’m really not looking forward to hearing what he has to say tomorrow, sometimes it’s cringe full. Don’t think I’ll tune in.
Have lost a good deal of respect. I don’t think they are comfortable or have the nous with scale and LF type issues and politics, it’s not them. I do however still think it’s an exceptional business and transformational. Great release this morning and is better and more worthwhile than the wild wild West of LFs would ever be long term. Money in the bank and solid growing recognition.
I’m more keen than ever and happy to wait for the amazing chemistry to get the Nobel prize, despite the CEOs weaknesses in certain areas.
I’d be interested to know what the test supplier breakdown is of the daily test numbers. Yesterday was 1,123,798 uk tests. The daily test number doesn’t seem to be reducing radically. Looks similar to back in April. Appreciate many will be PCR but it’s still a big number overall and it’s warm and sunny.
And that’s all we need for now Timster, thanks. Good concise summary. Onwards and upwards I’m sure.
With you on that. Think Roche Holdings is 300B MC
Announcing a new comms channel is only any good if you then use it and have sufficient content that you’re willing to publish, otherwise it simply provokes more dissent. I do hope they will be reasonably active with this over the coming weeks.
Geordieexpat, successful rollout of the LFTs would still be amazing but this wouldn't match the value of the therapeutic platforms which could take the business to the 10s of billions in value if they came off. I guess the growing enthusiasm for this is that has become that much closer now and is on the cusp.
Go kip out Doggy. It will all still be there in
the morning. The eventual outcome is inevitable, even if it might no be tomorrow. We’re a done deal and just a matter of over the line.
Of course we’re a bit shell shocked for the waiting but big things always come in the end.
Many thanks to the amazing researchers on our BB who have helped differentiate this stock from all of the rest out there.
Blimey. My first look since early this morn. Get the feeling this is AV6000 for something like this. That would be a global news event in time.
Whichever way, so pleased to be bit blue again.
Best to all.
Outstanding performance. I think one to enjoy for many years to come. Huge congrats to all.
Wonderful RNS. Could be making history very soon.
Good luck all and mostly those concerned in the trial.
Private Ryan, spot on. I think though that if one of those products proves successful it would be one of the biggest medical stories in many a year and considerably higher than a 1B market cap.
We are selling the best LFDs and the market is arguably going to grow with ease of use and home testing replacing the current PCR nightmare. I’ve just had to pay £800 for family tests for travel.
I remain hugely and ever more excited about the short and medium term.